Samalin Investment Counsel, LLC Gilead Sciences, Inc. Transaction History

Samalin Investment Counsel, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $40,865 - $46,027	-708 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$57.92 - $72.58 $9,556 - $11,975	-165 Reduced 18.9%	708 $42.1 Million
Q4 2021 Feb 15, 2022	BUY	$64.88 - $73.64 $259 - $294	4 Added 0.46%	873 $63.4 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $1,692 - $1,825	25 Added 2.96%	869 $60.7 Million
Q2 2021 Aug 12, 2021	BUY	$63.47 - $69.35 $53,568 - $58,531	844 New	844 $58,000
Q1 2021 May 11, 2021	SELL	$60.0 - $68.46 $38,220 - $43,609	-637 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$56.65 - $64.55 $68,149 - $77,653	-1,203 Reduced 65.38%	637 $37.2 Million
Q3 2020 Nov 10, 2020	BUY	$62.1 - $78.08 $114,264 - $143,667	1,840 New	1,840 $116,000
Q1 2020 May 04, 2020	SELL	$62.63 - $80.22 $31,690 - $40,591	-506 Closed	0 $0
Q4 2019 Feb 05, 2020	BUY	$61.62 - $67.78 $31,179 - $34,296	506 New	506 $32,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Samalin Investment Counsel, LLC, based on Form 13F filings with the SEC.

Stay updated on Samalin Investment Counsel, LLC with notifications on news.